Deutsche Bank AG Buys 54,360 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Deutsche Bank AG grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 357,479 shares of the company's stock after buying an additional 54,360 shares during the period. Deutsche Bank AG owned 0.44% of IDEXX Laboratories worth $147,796,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after buying an additional 37,734 shares in the last quarter. Bamco Inc. NY lifted its holdings in IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Invesco Ltd. lifted its holdings in IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares in the last quarter. Norges Bank purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $412,258,000. Finally, Northern Trust Corp lifted its holdings in IDEXX Laboratories by 18.6% in the 4th quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after purchasing an additional 143,369 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research report on Monday, April 14th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Finally, StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $524.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded up $0.29 during midday trading on Wednesday, reaching $509.42. 552,624 shares of the stock traded hands, compared to its average volume of 650,337. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market capitalization of $40.97 billion, a PE ratio of 47.74, a P/E/G ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company's 50 day moving average is $426.36 and its 200 day moving average is $429.96.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.71 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.